Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Sodium and chloride dependent glycine transporter 1 is a protein encoded by the SLC6A9 gene. The Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) pipeline drugs market research report provides comprehensive information on the Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics development with respective active and dormant or discontinued projects.
Glyt1 Pipeline Drugs Market Segmentation by Therapy Areas
The key therapy areas of the Glyt1 pipeline drugs market are central nervous system, genetic disorders, hematological disorders, and metabolic disorders. Central nervous system dominates the pipeline market.
Glyt1 Pipeline Drugs Market Analysis, by Therapy Areas
For more Glyt1 pipeline drugs market therapy areas insights, download a free report sample
Glyt1 Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanism of action of the Glyt1 pipeline drugs market is Sodium and Chloride Dependent Glycine Transporter 1 Inhibitor.
Glyt1 Pipeline Drugs Market Segmentation by Routes of Administration
The key route of administration in the Glyt1 pipeline drugs market is oral.
Glyt1 Pipeline Drugs Market Segmentation by Molecule Types
The key molecule type in the Glyt1 pipeline drugs market is small molecule.
Glyt1 Pipeline Drugs Market - Competitive Landscape
The leading companies in the Glyt1 pipeline drugs market are AbbVie Inc, Boehringer Ingelheim International GmbH, ConSynance Therapeutics Inc, Dart NeuroScience LLC, Disc Medicine Inc, Mental-Heal Ltd, and Pfizer Inc. Disc Medicine Inc dominates the market in 2022.
Glyt1 Pipeline Drugs Market Analysis, by Companies
To know more about the companies in the Glyt1 pipeline drugs market, download a free report sample
Glyt1 Pipeline Drugs Market Report Overview
Key Therapy Areas | Central Nervous System, Genetic Disorders, Hematological Disorders, and Metabolic Disorders |
Key Mechanism of Action | Sodium And Chloride Dependent Glycine Transporter 1 Inhibitor |
Key Route of Administration | Oral |
Key Molecule Type | Small Molecule |
Leading Companies | AbbVie Inc, Boehringer Ingelheim International GmbH, ConSynance Therapeutics Inc, Dart NeuroScience LLC, Disc Medicine Inc, Mental-Heal Ltd, and Pfizer Inc |
Scope
- The report provides a snapshot of the global therapeutic landscape for Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9).
- The report reviews Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing, and collaboration details & other developmental activities.
- The report reviews key players involved in Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics and enlists all their major and minor projects.
- The report assesses Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report summarizes all the dormant and discontinued pipeline projects.
- The report reviews the latest news and deals related to Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Identify and understand the targeted therapy areas and indications for Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9). Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Boehringer Ingelheim International GmbH
ConSynance Therapeutics Inc
Dart NeuroScience LLC
Disc Medicine Inc
Mental-Heal Ltd
Pfizer Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas of the Glyt1 pipeline drugs market?
The key therapy areas of the Glyt1 pipeline drugs market are central nervous system, genetic disorders, hematological disorders, and metabolic disorders.
-
What are the key mechanisms of action of the Glyt1 pipeline drugs market?
The key mechanism of action of the Glyt1 pipeline drugs market is Sodium And Chloride Dependent Glycine Transporter 1 Inhibitor.
-
What are the key routes of administration in the Glyt1 pipeline drugs market?
The key route of administration in the Glyt1 pipeline drugs market is oral.
-
What are the key molecule types in the Glyt1 pipeline drugs market?
The key molecule type in the Glyt1 pipeline drugs market is small molecule.
-
Which are the leading companies in the Glyt1 pipeline drugs market?
The leading companies in the Glyt1 pipeline drugs market are AbbVie Inc, Boehringer Ingelheim International GmbH, ConSynance Therapeutics Inc, Dart NeuroScience LLC, Disc Medicine Inc, Mental-Heal Ltd, and Pfizer Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.